Hugel, Inc. (KOSDAQ: A145020)
Health Care · Biotechnology · KR
₩245,000.00
-4.30% today · -21.5% 1Y
Hugel, Inc. (KOSDAQ: A145020) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.91B.
Over the last twelve months the share price has lost 21.5%, trading between 208.50K and 342.00K.
Tweenvest scores Hugel, Inc. across four factors: quality 75/100, value 67/100. Its strongest factor is quality.
A145020 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.91B
- Revenue (TTM)
- $309.68M
- P/E
- 16.76
- EPS
- 14,619.35
- Dividend yield
- —
- Beta (5Y)
- 0.56
- 52-week high
- ₩342,000.00
- 52-week low
- ₩208,500.00
- Avg volume (3M)
- —
- Shares outstanding
- 10.80M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.20 | +1.16% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.83 | +2.12% |
Figures last refreshed Aug 18, 2026.